Listen to an audio podcast of the September 12th, 2024 FDA Drug Safety Communication on rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause.
Similar Posts
FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies
Proposed removal of risk statements about cardiovascular diseases, breast cancer, and probable dementia from the boxed warnings, as well as other proposed safety-related labeling changes, to clarify the benefit/risk considerations for these drugs.Xtreme Tools International, Inc. – 706053 – 06/25/2025
CGMP/Finished Pharmaceuticals/AdulteratedProject Orbis
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.
Ultra Seal Corporation – 624650 – 09/25/2024
CGMP/Finished Pharmaceuticals/AdulteratedInfusion Pump Recall: Zyno Medical Removes Certain Z-800 Series Infusion Pumps due to Software Issue
Infusion pumps released with incorrect software can experience unexpected performance problems, including issues with essential functions and risk measures.